Neoadjuvant (Early Stage) Breast Cancer

The EMPOWHER-208 trial is a global, Phase 2 study evaluating the efficacy and safety of zanidatamab when combined with chemotherapy, in treating people who have HER2-positive, early-stage breast cancer.

For more information, please visit:
https://clinicaltrials.gov/study/NCT07102381